NewCelX

A biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.

Health Tech & Life Sciences
Acquired by NLS Pharmaceutics
Public Kloten, Switzerland Founded 2025
Last updated 2026-07-26
Total raised
$5.9M
Last: Undisclosed Round 2026-04
Stage
Public
Founded
2025
Headcount
11
HQ
Kloten, Switzerland
Sector
Health Tech & Life Sciences

About

NewCelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes and neurodegenerative diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments. NewCelX was formed on October 30, 2025, through the merger of NLS Pharmaceutics Ltd. from Zurich, Switzerland, and Kadimastem Ltd. from Nes Ziona, Israel.

Funding history · 7 rounds · $5.9M total

2025-09
Follow-on PO Undisclosed
2024-03
Follow-on PO Undisclosed
2022-04
Follow-on PO Undisclosed
2021-02
Follow-on PO Undisclosed
2018-10
Grant $750K
2018-09
PIPE $5.2M
★ Arik Hasson★ Yigal Fatran★ Julien Ruggieri★ Yehuda Feinberg★ Dr. Michal Izrael★ Michel and Claire Revel★ Altshuler Shaham Investment House
2013-05
Follow-on PO Undisclosed

Headcount over time

From 40 (2018-09) to 29 (2026-03) · -11 (-27%) · 45 points · source: Finder history + radar grounding
500 2018-09 2026-03

Q&A

What is NewCelX's primary focus?
NewCelX is a biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes and neurodegenerative diseases.
When was NewCelX formed and how?
NewCelX was formed on October 30, 2025, through the merger of NLS Pharmaceutics Ltd. from Zurich, Switzerland, and Kadimastem Ltd. from Nes Ziona, Israel.
What is the current employee count for NewCelX?
NewCelX currently has 11-50 employees.
What is the total amount of funding NewCelX has raised to date?
NewCelX has raised a total of $45,350,000 USD.
Who are some of the key executives at NewCelX?
Key executives at NewCelX include Ronen Twito (Executive Chairman & Chief Executive Officer), Alexander C. Zwyer (Chief Business Officer & Executive Director), and Omri Hagai (Chief Financial Officer).
Has NewCelX been involved in any public offerings?
Yes, NewCelX has had several public offerings, with the most recent one in September 2025.

Team · 22

Michel Revel
Founder · Co-Founder, VP R&D
Ronen Twito
Executive Chairman & Chief Executive Officer
LinkedIn ↗
Alexander C. Zwyer
Chief Business Officer & Executive Director
Omri Hagai
Chief Financial Officer
Kfir Molakandov
Vice President of R&D
Ariel Revel
Medical Director
Eric Konofal
Head of DOXA Program
Ronen Twito
Executive Chairman & Chief Executive Officer
Michel Revel
Director & Chief Scientific Officer
Alexander Zwyer
Director & Chief Business Officer
Olivier Samuel
Independent Director
Eran Iohan
Independent Director
Liora Oren
Independent Director
Tammy Galili
Director
Julien Boisdron
Chief Medical Officer, Roche (Scientific Advisory Board)
Tamir Ben-Hur
Associate Director, Hadassah BrainLabs (Scientific Advisory Board)
Jeremy Shefner
Chief Medical Officer, Barrow Neurological Institute (Scientific Advisory Board)
Camillo Ricordi
Chief of the Division of Cellular Transplantation, University of Miami Miller School of Medicine (Scientific Advisory Board)
Benjamin Reubinoff
Member of Scientific Advisory Board
Eddy Karnieli
Member of Scientific Advisory Board
Danielle Melloul
Member of Scientific Advisory Board
Jeanne F. Loring
Member of Scientific Advisory Board

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B

Highlights

Patents

Tags

pharma-companiesstem-cellsdiabetesdegenerative-diseasesbioprocessneurologycell-therapyregenerative-medicinebiological-therapyamyotrophic-lateral-sclerosis-alsbiotechnologymedical-researchhealthcare
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitenewcelx.com/
LinkedInlinkedin.com/company/1515403

Identifiers & details

Legal nameNewcelX Ltd.
Founded2025-10
Employees (exact)11

Acquisitions & public offerings

Acquired by NLS Pharmaceutics 2025-10

Radar intelligence

Web history (Wayback)

Domainnewcelx.com

Certificate / subdomain footprint

Subdomains3

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514192558
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated2008-10-06
Purposeלעסוק בכל עיסוק חוקי למעט בסוגי עסקים שפורטו בתקנון
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2011
Active charges / liens0
Registry events0
Registered addressספיר פנחס 7 נס ציונה